Sparfloxacin - positive economic impact predicted

Abstract

T he cost of treating community-acquired pneumonia may be reduced once sparfloxacin [Zagam ®; Rhône-Poulenc Rorer, Dainippon] is introduced into general practice. the lower costs associated with the use of this new agent were indicated in a cost-effectiveness study presented at the 4th European Respiratory Society Annual Congress [ Nice, France; October 1994 ]. The French data is of particular interest, as France recently became the first European country to launch sparfloxacin.